Bifidobacterium longum CBi0703:
A Microbiotic Innovation in Osteoarthritis
- Control group: received H20
- Intervention group: received inactivated culture of Bifidobacterium Longum CBi0703
In addition to mechanical and other risk factors, accumulating evidence suggests that the presence of chronic low-grade inflammation has a role in the development of osteoarthritis. This low-grade inflammation appears to be related to the composition of the gut microbiota¹¹.
An imbalance of the gut microbiota, known as dysbiosis, can lead to increased permeability of the intestinal wall. This facilitates the movements of pro-inflammatory molecules such as endotoxins into the blood. These endotoxins can activate the immune system and cause systemic low-grade inflammation, which may ultimately lead to breakdown of the joint structure5 6 7.
The link between dysbiosis and osteoarthritis offers new therapeutic opportunities to help patients manage the condition. By modulating the composition of the gut bacteria it may be possible to reduce the progression of osteoarthritis5.
† Dysbiosis: Adverse alterations in the diversity, structure or function of gut microbiota that is associated with disease
320 male and females with mild-moderate osteoarthritis
1 capsule/day (Bifidobacterium longum CBi0703 + Vitamin C)
(Visual Analogue Scale (VAS))